Toggle Main Menu Toggle Search

Open Access padlockePrints

Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration

Lookup NU author(s): Andrew Browning

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Aim To analyse the benefit of intravitreal ranibizumab over 4 years for patients with neovascular age-related macular degeneration (AMD).Methods A retrospective case note review of all patients who started treatment between August 2007 and September 2009 in our unit, minimum follow-up 2 years, maximum 4 years. The main outcome measures were: numbers of patients with different levels of vision, changes in visual acuity, number of treatments and numbers remaining under follow-up.Results 1086 eyes of 1017 patients received treatment. Numbers of patients remaining under follow-up were 892/1017 (87.71%) at 12 months, 730/1017 (71.78%) at 24 months, 468/730 (64.11%) at 36 months and 110/217 (50.69%) at48 months. The main reasons for patients no longer being under follow-up were the consequences of old age or transfer of care. 50% of patients had 6/18 or better over 4 years. Patients received on average 5.79 +/- 2.53, 9.15 +/- 3.79, 11.22 +/- 4.92 and 13.7 +/- 7.84 injections by 12, 24, 36 and 48 months, respectively.Conclusions We suggest that the numbers of patients with a particular level of vision may best reflect the actual benefit of AMD treatment provided by a service. Long-term follow-up is required as only 72/730 (10%) had been discharged at 36 months, half of whom had good vision of greater than 60 letters. 83% and 65% of patients needed treatment in the third and fourth year. Follow-up may be for the rest of the patients' life or at some point they may no longer be well enough to attend.


Publication metadata

Author(s): Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ

Publication type: Article

Publication status: Published

Journal: British Journal of Ophthalmology

Year: 2012

Volume: 96

Issue: 12

Pages: 1469-1473

Print publication date: 01/12/2012

Online publication date: 21/09/2012

Acceptance date: 18/08/2012

ISSN (print): 0007-1161

ISSN (electronic): 1468-2079

Publisher: BMJ Publishing Group

URL: http://dx.doi.org/10.1136/bjophthalmol-2012-302167

DOI: 10.1136/bjophthalmol-2012-302167


Altmetrics

Altmetrics provided by Altmetric


Share